Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty

Lenihan, Daniel J.; Hartlage, Gregory; DeCara, Jeanne M.; Blaes, Anne; Finet, J. Emanuel; Lyon, Alexander R.; Cornell, Robert F.; Moslehi, Javid; Oliveira, Guilherme H.; Murtagh, Gillian; Fisch, Michael J.; Zeevi, Gary R.; Iakobishvili, Zaza; Witteles, Ron; Patel, Aarti; Harrison, Eric E.; Fradley, Michael G.; Curigliano, Giuseppe; Lenneman, Carrie Geisberg; Magalhães, Andreia; Krone, Ron; Porter, Charles B.; Parasher, Susmita; Dent, Susan; Douglas, Pamela S.; Carver, Joseph R.

doi:10.1016/j.cardfail.2016.03.012

Cited by 56 publications

(45 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…54 This non-accredited fellowship consists of 12 months of clinical exposure, didactic teaching and research. The curriculum is designed so that upon completion of the fellowship, trainees possess expertise in all aspects of cardio-oncology.…”

Section: Cardio-oncology Program - Educationmentioning

confidence: 99%

Developing a comprehensive Cardio-Oncology Program at a Cancer Institute: the Moffitt Cancer Center experience

et al. 2017

Self Cite

View full text Add to dashboard Cite

Cardio-oncology is a multidisciplinary field focusing on the management and prevention of cardiovascular complications in cancer patients and survivors. While the initial focus of this specialty was on heart failure associated with anthracycline use, novel anticancer agents are increasingly utilized and are associated with many other cardiotoxicities including hypertension, arrhythmias and vascular disease. Since its inception, the field has developed at a rapid pace with the establishment of programs at many major academic institutions and community practices. Given the complexities of this patient population, it is important for providers to possess knowledge of not only cardiovascular disease but also cancer subtypes and their specific therapeutics. Developing a cardio-oncology program at a stand-alone cancer center can present unique opportunities and challenges when compared to those affiliated with other institutions including resource allocation, cardiovascular testing availability and provider education. In this review, we present our experiences establishing the cardio-oncology program at Moffitt Cancer Center and provide guidance to those individuals interested in developing a program at a similar independent cancer institution.

show abstract

Section: Cardio-oncology Program - Educationmentioning

confidence: 99%

Developing a comprehensive Cardio-Oncology Program at a Cancer Institute: the Moffitt Cancer Center experience

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Calcium is often deposited with the fatty substances, producing calcified plaques. [2,3]. Since the 1940s, researchers have found that the imbalance in the metabolism or transfusion of blood cholesterol has a significant effect on the bloodstream disease [4,5].Studies also indicate that the amount and nature of food has a clear effect on the level of blood cholesterol, as saturated fatty acids, working to raise the level of cholesterol.…”

Section: Introductionmentioning

confidence: 99%

Study of LCAT and some biochemical parameters in cardiovascular patient

Al-Juraisy¹,

Saleh²

2020

Tikrit J. Pure Sci.

View full text Add to dashboard Cite

The Clinical study included individuals (m23ales and females aged 25-75y) with cardiovascular disease. The activity of Lecithin: cholesterol acyl transferase (LCAT) and glutathione peroxidase(GPx) was estimated, in addition to the level of apolipoprotein AI (apo AI), apolipoprotein B100 (apoB100), total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-c), low density lipoprotein-cholesterol (LDL-c), glutathione (GSH), peroxy nitrate (PN), malondialdehyde (MDA), glucose and certain elements (Zn, Cu, Mg and Co) in blood serum. The results showed that there was a significant decrease in the activity of LCAT and GPx, and the level of apoAI, HDL-c, GSH, Zn and Mg. on the other hand, it was shown that there was a significant increase in the level of apoB100, TC, TG, LDL-c, PN, Glu, Cu and Co but on unsignificant change in the level of MDA for both male and females. http://dx.doi.org/10.25130/tjps.25.2020.026

show abstract

“…The research gaps in novel cancer treatment‐related cardiotoxicity range from basic, translational, clinical, and epidemiologic sciences to cancer patients, medical professionals, research communities, pharmaceutical industries, regulatory bodies, and research funding agencies. In response to ongoing clinical challenges, “cardio‐oncology” or “onco‐cardiology” represents a new multidisciplinary discipline in recent decades and is a newer frontier in clinical medicine leading to advances in clinical care, medical education, and dual subspecialist training programs . The subspecialty harbors more questions than answers; thus, enormous research opportunities are embedded in the field .…”

Section: Introductionmentioning

confidence: 99%

“…In response to ongoing clinical challenges, "cardio-oncology" or "onco-cardiology" represents a new multidisciplinary discipline in recent decades 92,93 and is a newer frontier in clinical medicine leading to advances in clinical care, medical education, and dual subspecialist training programs. [94][95][96] The subspecialty harbors more questions than answers; thus, enormous research opportunities are embedded in the field. 76 The research is expected to address gaps from basic, translational, and clinical studies to epidemiological studies and to exploit the synergistic interactions among multiple disciplines.…”

mentioning

confidence: 99%

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Zheng

Kros

2017

Medicinal Research Reviews

View full text Add to dashboard Cite

To date, five cancer treatment modalities have been defined. The three traditional modalities of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two modern modalities include molecularly targeted therapy (the fourth modality) and immunotherapy (the fifth modality). The cardiotoxicity associated with conventional chemotherapy and radiotherapy is well known. Similar adverse cardiac events are resurging with the fourth modality. Aside from the conventional and newer targeted agents, even the most newly developed, immune‐based therapeutic modalities of anticancer treatment (the fifth modality), e.g., immune checkpoint inhibitors and chimeric antigen receptor (CAR) T‐cell therapy, have unfortunately led to potentially lethal cardiotoxicity in patients. Cardiac complications represent unresolved and potentially life‐threatening conditions in cancer survivors, while effective clinical management remains quite challenging. As a consequence, morbidity and mortality related to cardiac complications now threaten to offset some favorable benefits of modern cancer treatments in cancer‐related survival, regardless of the oncologic prognosis. This review focuses on identifying critical research‐practice gaps, addressing real‐world challenges and pinpointing real‐time insights in general terms under the context of clinical cardiotoxicity induced by the fourth and fifth modalities of cancer treatment. The information ranges from basic science to clinical management in the field of cardio‐oncology and crosses the interface between oncology and onco‐pharmacology. The complexity of the ongoing clinical problem is addressed at different levels. A better understanding of these research‐practice gaps may advance research initiatives on the development of mechanism‐based diagnoses and treatments for the effective clinical management of cardiotoxicity.

show abstract

Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty

Cited by 56 publications

References 38 publications

Developing a comprehensive Cardio-Oncology Program at a Cancer Institute: the Moffitt Cancer Center experience

Developing a comprehensive Cardio-Oncology Program at a Cancer Institute: the Moffitt Cancer Center experience

Study of LCAT and some biochemical parameters in cardiovascular patient

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Contact Info

Product

Resources

About